lymphoma
Conditions
Interventions
Test group:chidamid, etoposide, cytarabine, and cyclophosphamide, patients with CD20(+) were given rituximab too.
Sponsors
Dongguan Kanghua Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with lymphoma confirmed by pathology or histopytology; 2. Age 12-75 years old; 3. Patients with IPI score of 3-5, double-expression or double-triple strike diffuse large B-cell lymphoma, or relapsed/refractory lymphoma; 4.There should be a definite evaluation of the curative effect of prior treatment before enrollment,; 5. Estimated survival >=1 month; 6. Liver function: transaminase and bilirubin =3 times the upper limit of normal value; Renal function: glomerular filtration rate >=30ml/min.
Exclusion criteria
Exclusion criteria: 1. The expected survival time < 1 month; 2. Patients who had serious heart disease; 3. Patients who have had malignant tumors within 5 years; 4. Pregnant or lactating women; 5. Do not receive Chidamide therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival;Toxic and side effect; | — |
Countries
China
Contacts
Public ContactHuang Shunhua
Dongguan Kanghua Hospital
Outcome results
None listed